---
title: "Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285422995.md"
description: "Chardan Capital's Geulah Livshits has reiterated a Buy rating on Taysha Gene Therapies (TSHA) with a price target of $12.00. Livshits, who focuses on the Healthcare sector, has an average return of 12.6% and a 38.09% success rate on stock recommendations. Taysha Gene Therapies holds a Strong Buy consensus among analysts, with a price target consensus of $12.44."
datetime: "2026-05-06T18:55:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285422995.md)
  - [en](https://longbridge.com/en/news/285422995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285422995.md)
---

# Chardan Capital Remains a Buy on Taysha Gene Therapies (TSHA)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Taysha Gene Therapies, with a price target of $12.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Iovance Biotherapeutics, and Rocket Pharmaceuticals. According to TipRanks, Livshits has an average return of 12.6% and a 38.09% success rate on recommended stocks.

Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $12.44.

### Related Stocks

- [TSHA.US](https://longbridge.com/en/quote/TSHA.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)
- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)